Boston Scientific Corp

Market Summary

USD54.93-0.10

Market Closed

-0.18%

BSX Alerts

3 major insider sales recently.

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Alerts

3 major insider sales recently.

BSX Valuation

Market Cap

79.4B

Price/Earnings (Trailing)

87.11

Price/Sales (Trailing)

5.77

EV/EBITDA

26.13

Price/Free Cashflow

46.81

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

11.28%

Return on Equity

Return on Assets

2.71%

Free Cashflow Yield

2.14%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

13.8B

Revenue Y/Y

11.26%

Revenue Q/Q

-2%

BSX Earnings

Earnings (TTM)

912.0M

Earnings Y/Y

3.85%

Earnings Q/Q

-14.01%

Price Action

Last 7 days

-1.5%

Last 30 days

5.5%

Last 90 days

2.2%

Trailing 12 Months

20.6%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.29

Debt/Equity

0.47

Debt/Cashflow

0.25

BSX Investor Care

Shares Dilution (1Y)

1.15%

Diluted EPS (TTM)

0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.0B	13.4B	13.8B	0
2022	12.2B	12.3B	12.6B	12.7B
2021	10.1B	11.2B	11.5B	11.9B
2020	10.8B	10.2B	10.1B	9.9B
2019	9.9B	10.1B	10.4B	10.7B
2018	9.3B	9.5B	9.7B	9.8B
2017	8.6B	8.7B	8.8B	9.0B
2016	7.7B	8.0B	8.2B	8.4B
2015	7.4B	7.3B	7.4B	7.5B
2014	7.2B	7.2B	7.3B	7.4B
2013	7.1B	7.1B	7.1B	7.1B
2012	7.6B	7.4B	7.3B	7.2B
2011	7.8B	7.8B	7.8B	7.6B
2010	8.1B	8.0B	7.9B	7.8B
2009	8.0B	8.1B	8.1B	8.2B
2008	8.3B	8.2B	8.1B	8.1B
2007	0	0	0	8.4B

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for BSX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 03, 2023	mirviss jeffrey b.	acquired	-	-	649	evp&pres, periph intervent
Dec 03, 2023	mirviss jeffrey b.	sold (taxes)	-16,617	56.14	-296	evp&pres, periph intervent
Nov 20, 2023	butcher arthur c	sold	-447,509	54.06	-8,278	evp& grp pres, medsurg & apac
Nov 20, 2023	butcher arthur c	acquired	66,606	17.26	3,859	evp& grp pres, medsurg & apac
Nov 15, 2023	carruthers wendy	sold	-632,269	54.1744	-11,671	evp, human resources
Nov 15, 2023	carruthers wendy	acquired	94,953	14.818	6,408	evp, human resources
Nov 08, 2023	mirviss jeffrey b.	gifted	-	-	-4,000	evp&pres, periph intervent
Nov 06, 2023	mahoney michael f	sold	-5,951,980	52.507	-113,356	chairman, president & ceo
Nov 06, 2023	mahoney michael f	acquired	1,662,530	14.6664	113,356	chairman, president & ceo
Oct 16, 2023	carruthers wendy	sold	-581,063	49.7869	-11,671	evp, human resources

Which funds bought or sold BSX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	Raleigh Capital Management Inc.	added	3.74	2,096	166,908	0.09%
Dec 06, 2023	CITIGROUP INC	added	2.5	70,409	122,224,000	0.09%
Dec 04, 2023	Phoenix Holdings Ltd.	added	85.77	6,402,050	14,188,700	0.13%
Dec 04, 2023	TUCKER ASSET MANAGEMENT LLC	added	53.12	856	2,587	-%
Dec 01, 2023	B. Riley Wealth Advisors, Inc.	reduced	-60.79	-1,385,300	859,056	0.02%
Nov 28, 2023	ASB Consultores, LLC	sold off	-100	-292,519	-	-%
Nov 28, 2023	IMA Wealth, Inc.	reduced	-1.59	-70,053	1,707,180	0.44%
Nov 27, 2023	OKABENA INVESTMENT SERVICES INC	sold off	-100	-16,822	-	-%
Nov 27, 2023	BANQUE PICTET & CIE SA	reduced	-12.27	-3,619,040	21,573,900	0.26%
Nov 27, 2023	TRUST CO OF VERMONT	added	43.51	69,172	241,719	0.02%

Latest Funds Activity

Are funds buying BSX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BSX

No. of Funds

Schedule 13G FIlings of Boston Scientific Corp

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	blackrock inc.	9.6%	137,802,646	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.29%	118,773,794	SC 13G/A
Feb 08, 2023	massachusetts financial services co /ma/	5.8%	82,467,469	SC 13G/A
Feb 06, 2023	wellington management group llp	4.03%	57,736,340	SC 13G/A
Jan 24, 2023	blackrock inc.	9.8%	140,116,265	SC 13G/A
Feb 09, 2022	vanguard group inc	7.83%	111,621,630	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 08, 2022	blackrock inc.	9.0%	127,917,655	SC 13G/A
Feb 04, 2022	wellington management group llp	5.22%	74,421,509	SC 13G/A

Recent SEC filings of Boston Scientific Corp

View All Filings

Date Filed	Form Type	Document
Dec 07, 2023	4	Insider Trading
Dec 04, 2023	4	Insider Trading
Dec 04, 2023	4	Insider Trading
Nov 22, 2023	8-K	Current Report
Nov 21, 2023	4	Insider Trading
Nov 20, 2023	144	Notice of Insider Sale Intent
Nov 16, 2023	4	Insider Trading
Nov 15, 2023	144	Notice of Insider Sale Intent
Nov 09, 2023	4	Insider Trading
Nov 07, 2023	4	Insider Trading

BSX Fair Value

Peers (Alternatives to Boston Scientific Corp)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.9B	40.0B	9.79%	-0.70%	35.24	4.55	-11.26%	-34.57%
BDX	71.3B	19.4B	-8.82%	-4.53%	44.09	3.79	2.66%	-16.58%
BAX	18.3B	15.0B	6.81%	-29.70%	7.06	1.22	3.01%	209.09%
ALGN	16.9B	3.8B	9.66%	15.63%	46.7	4.45	-1.48%	-28.97%
MID-CAP
HSIC	9.3B	12.7B	13.63%	-12.11%	21	0.74	0.68%	-30.25%
BIO	8.9B	2.7B	2.35%	-23.26%	-55.55	3.25	-3.01%	97.36%
ATR	8.3B	3.4B	1.55%	18.98%	29.56	2.41	3.13%	18.17%
XRAY	6.9B	3.9B	14.40%	9.17%	-31.57	1.75	-2.62%	73.28%
AXNX	2.9B	342.6M	8.31%	-12.22%	-244.83	8.56	42.19%	84.14%
PDCO	2.5B	6.6B	-12.97%	-7.64%	12.41	0.38	2.61%	0.62%
SMALL-CAP
AHCO	1.1B	3.1B	3.77%	-63.31%	-2.53	0.35	7.95%	-550.16%
ANIK	329.0M	163.3M	7.10%	-27.48%	-13.39	2.01	7.14%	-56.09%
ANGO	282.7M	335.9M	6.52%	-42.04%	43.86	0.84	4.71%	116.39%
APYX	72.1M	50.3M	-18.43%	13.66%	-4.75	1.43	3.23%	20.81%
AEMD	5.2M	3.8M	8.25%	-44.93%	-0.45	1.37	17.30%	10.67%

Boston Scientific Corp News

Latest updates

Clayton County Register • 08 Dec 2023 • 02:21 pm • 10 hours ago

Boston Scientific Corp Sees Modest Increase in Stock Price

Stockhouse Publishing • 05 Dec 2023 • 03:08 pm • 3 days ago

2023-12-05 | NYSE:BSX | Press Release | Boston Scientific Corp

Mergers & Acquisitions • 04 Dec 2023 • 12:00 pm • 4 days ago

Buyers Will Adjust to High Interest Rates in 2024, Experts Say

Fitch Ratings • 01 Dec 2023 • 03:54 pm • 7 days ago

Fitch Upgrades Boston Scientific's ST IDR to 'F1'; Affirms LT IDR at ...

Nasdaq • 30 Nov 2023 • 03:53 pm • 8 days ago

BSX January 2024 Options Begin Trading

Nasdaq • 30 Nov 2023 • 12:00 am • 9 days ago

Boston Scientific Corp. Shares Climb 0.1% Past Previous 52-Week ...

Morningstar • 21 Nov 2023 • 08:00 am • 17 days ago

MDT Stock - Medtronic Stock Price Quote - NYSE

Yahoo Finance • 17 Nov 2023 • 08:00 am • 21 days ago

Insider Sell: EVP Wendy Carruthers Sells 11,671 Shares of Boston ...

Nasdaq • 17 Nov 2023 • 08:00 am • 21 days ago

Boston Scientific Closes Acquisition Of Relievant Medsystems

MarketWatch • 16 Nov 2023 • 08:00 am • 22 days ago

Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains

Yahoo Finance • 14 Nov 2023 • 08:00 am • 24 days ago

Orbimed Advisors LLC Bolsters Portfolio with Alpine Immune ...

GuruFocus.com • 14 Nov 2023 • 08:00 am • 24 days ago

Steven Cohen's Point72 Asset Management Adjusts Portfolio ...

GuruFocus.com • 13 Nov 2023 • 08:00 am • 25 days ago

Unveiling Boston Scientific (BSX)'s Value: Is It Really Priced Right ...

Barron's • 13 Nov 2023 • 08:00 am • 25 days ago

S&P 500 Futures Decline in Premarket Trading; monday.com, Penumbra Lead

MarketWatch • 10 Nov 2023 • 08:00 am • 28 days ago

Teleflex Inc. stock rises Friday, still underperforms market

Financials for Boston Scientific Corp

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-2.0%	3,527	3,599	3,389	3,242	3,170	3,244	3,026	3,127	2,932	3,077	2,752	2,709	2,659	2,003	2,543	2,904	2,707	2,631	2,493	2,561	2,393
Gross Profit	-4.6%	2,426	2,542	2,349	2,232	2,191	2,233	2,071	2,155	2,032	2,132	1,858	1,709	1,790	1,212	1,737	2,054	1,930	1,873	1,763	1,833	1,720
Operating Expenses	-14.5%	1,733	2,028	1,797	1,830	1,833	1,810	1,605	1,975	1,645	1,870	1,488	1,659	1,995	1,283	1,591	1,844	1,547	1,489	1,222	1,512	1,333
S&GA Expenses	-8.3%	1,242	1,354	1,215	1,163	1,132	1,165	1,060	1,153	1,066	1,121	1,019	1,027	984	798	978	1,092	1,012	968	869	953	870
EBITDA Margin	-100.0%	-	0.22*	0.22*	0.22*	0.20*	0.22*	0.21*	0.21*	0.24*	0.18*	0.17*	0.14*	0.12*	0.15*	0.17*	-	-	-	-	-	-
Interest Expenses	-5.7%	66.00	70.00	65.00	64.00	63.00	64.00	279	87.00	86.00	86.00	82.00	96.00	86.00	91.00	88.00	180	95.00	89.00	109	65.00	58.00
Income Taxes	-32.7%	105	156	131	256	57.00	85.00	45.00	26.00	64.00	-37.00	-16.00	96.00	-72.00	-33.00	12.00	-4,002	-35.00	-9.00	33.00	-90.00	24.00
Earnings Before Taxes	43.2%	610	426	444	396	245	345	156	119	483	149	325	307	-227	-181	22.00	-6.00	91.00	145	457	296	456
EBT Margin	-100.0%	-	0.11*	0.11*	0.09*	0.07*	0.09*	0.07*	0.09*	0.11*	0.05*	0.02*	-0.01*	-0.04*	-0.01*	0.02*	-	-	-	-	-	-
Net Income	-100.0%	-	270	314	140	188	260	110	95.00	419	186	341	210	-155	-147	11.00	3,996	126	154	424	386	432
Net Income Margin	-100.0%	-	0.07*	0.07*	0.06*	0.05*	0.07*	0.07*	0.09*	0.10*	0.05*	0.02*	-0.01*	0.37*	0.39*	0.40*	-	-	-	-	-	-
Free Cashflow	-100.0%	-	515	79.00	595	320	202	-179	212	358	537	209	514	594	201	-177	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	1.3%	34,043	33,601	32,892	32,469	31,947	32,189	32,337	32,229	31,877	31,168	30,900	30,777	30,845	30,823	30,113	30,565	26,756	24,309	23,802	20,999	20,379
Current Assets	10.5%	6,504	5,886	5,704	5,760	5,144	5,083	5,065	6,317	6,229	6,758	6,101	6,694	6,160	5,803	4,823	4,699	4,847	6,334	6,234	4,003	3,971
Cash Equivalents	165.7%	1,132	426	570	928	338	276	325	2,168	1,947	2,675	2,016	1,734	2,022	1,724	370	607	277	123	139	829	168
Inventory	6.8%	2,404	2,250	2,050	1,867	1,788	1,752	1,736	1,610	1,603	1,430	1,407	1,351	1,472	1,516	1,628	1,579	1,566	1,300	1,228	1,166	1,134
Net PPE	4.0%	2,635	2,534	2,478	2,446	2,273	2,246	2,265	2,252	2,109	2,082	2,053	2,084	2,064	2,079	2,098	2,079	1,942	1,820	1,782	1,782	1,730
Goodwill	-0.4%	13,608	13,659	13,269	12,920	12,852	12,883	12,949	11,988	11,820	10,874	10,868	9,951	10,137	10,101	10,098	10,176	10,015	8,451	8,179	7,911	7,588
Current Liabilities	0.4%	4,579	4,562	4,083	3,803	3,549	3,883	4,275	4,274	4,022	4,073	3,393	3,681	3,302	3,108	3,976	4,866	4,254	4,850	4,479	5,260	5,082
Long Term Debt	-1.3%	8,386	8,494	8,495	8,915	8,564	8,802	9,067	8,804	8,824	8,847	9,082	9,130	9,325	9,278	9,331	8,592	9,590	7,591	7,590	4,803	4,806
Shareholder's Equity	3.6%	18,886	18,226	17,850	17,573	17,640	17,251	16,735	16,622	16,462	15,942	15,719	15,326	15,564	15,616	13,804	13,877	9,699	9,425	9,233	8,726	8,289
Retained Earnings	266.7%	315	-189	-450	-750	-876	-1,050	-1,296	-1,392	-1,473	-1,878	-2,050	-2,378	-2,574	-2,405	-2,252	-2,253	-6,249	-6,375	-6,528	-6,953	-7,339
Additional Paid-In Capital	0.6%	20,573	20,441	20,356	20,289	20,219	20,103	20,043	19,986	19,930	19,817	19,750	19,732	19,687	19,590	17,589	17,561	17,510	17,422	17,374	17,346	17,304
Shares Outstanding	-100.0%	-	1,446	1,436	-	1,432	1,430	1,428	-	1,424	1,421	1,419	-	1,431	1,411	1,397	1,395	1,393	1,391	1,388	1,385	1,383
Minority Interest	-6.2%	243	259	259	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	6.1%	698	658	190	807	470	307	-58.00	478	465	643	284	673	643	269	-77.00	692	502	292	350	19.00	501
Share Based Compensation	-1.7%	59.00	60.00	55.00	55.00	58.00	55.00	52.00	49.00	51.00	47.00	47.00	42.00	40.00	46.00	42.00	41.00	42.00	38.00	36.00	36.00	36.00
Cashflow From Investing	76.5%	-197	-840	-484	-183	-225	-29.00	-1,574	-461	-1,207	-	71.00	-147	-129	-59.00	-76.00	-49.00	-3,962	-620	-410	-595	-662
Cashflow From Financing	-62.8%	16.00	43.00	-69.00	1.00	-199	-344	-6.00	-8.00	6.00	2.00	-95.00	-819	-249	1,105	256	-724	1,314	256	2,127	425	151
Dividend Payments	-100.0%	-	14.00	14.00	13.00	14.00	14.00	14.00	13.00	14.00	14.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-

BSX Income Statement

2023-09-30

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 3,527	$ 3,170	$ 10,515	$ 9,440
Cost of products sold	1,101	979	3,198	2,945
Gross profit	2,426	2,191	7,317	6,495
Operating expenses:
Selling, general and administrative expenses	1,242	1,132	3,811	3,357
Research and development expenses	356	339	1,051	993
Royalty expense	11	11	35	34
Amortization expense	208	202	620	604
Intangible asset impairment charges	1	125	58	132
Contingent consideration net expense (benefit)	12	20	43	68
Restructuring net charges (credits)	15	4	51	18
Litigation-related net charges (credits)	(111)	0	(111)	42
Operating expenses	1,733	1,833	5,558	5,248
Operating income (loss)	693	358	1,759	1,247
Other income (expense):
Interest expense	(66)	(63)	(200)	(406)
Other, net	(18)	(51)	(78)	(96)
Income (loss) before income taxes	610	245	1,480	745
Income tax expense (benefit)	105	57	392	188
Net income (loss)	504	188	1,088	558
Preferred stock dividends	0	(14)	(23)	(42)
Net income (loss) attributable to noncontrolling interests	0	0	0	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 505	$ 174	$ 1,065	$ 516
Net income (loss) per common share — basic	$ 0.34	$ 0.12	$ 0.74	$ 0.36
Net income (loss) per common share — diluted	$ 0.34	$ 0.12	$ 0.73	$ 0.36
Weighted-average shares outstanding
Basic	1,464.5	1,431.6	1,448.8	1,429.7
Diluted	1,475.0	1,440.0	1,459.1	1,438.7

BSX Balance Sheet

2023-09-30

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 952	$ 928
Trade accounts receivable, net	2,101	1,970
Inventories	2,404	1,867
Prepaid income taxes	307	264
Other current assets	741	731
Total current assets	6,504	5,760
Property, plant and equipment, net	2,635	2,446
Goodwill	13,608	12,920
Other intangible assets, net	5,849	5,902
Deferred tax assets	3,840	3,942
Other long-term assets	1,605	1,500
TOTAL ASSETS	34,043	32,469
Current liabilities:
Current debt obligations	513	20
Accounts payable	929	862
Accrued expenses	2,255	2,160
Other current liabilities	882	761
Total current liabilities	4,579	3,803
Long-term debt	8,386	8,915
Deferred income taxes	91	144
Other long-term liabilities	1,858	2,035
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of September 30, 2023 and 10,062,500 shares as of December 31, 2022	0	0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,728,158,524 shares as of September 30, 2023 and 1,696,633,993 shares as of December 31, 2022	17	17
Treasury stock, at cost - 263,289,848 shares as of September 30, 2023 and December 31, 2022	(2,251)	(2,251)
Additional paid-in capital	20,573	20,289
Retained earnings/(Accumulated deficit)	315	(750)
Accumulated other comprehensive income (loss), net of tax	231	269
Total stockholders’ equity	18,886	17,573
Noncontrolling interests	243	0
Total equity	19,129	17,573
TOTAL LIABILITIES AND EQUITY	$ 34,043	$ 32,469

About Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Michael F. Mahoney
WEBSITE	www.bostonscientific.com
EMPLOYEES	45000

Boston Scientific Corp Frequently Asked Questions

What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Thu Dec 07 2023, market cap of Boston Scientific Corp is 79.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart. The fair value of Boston Scientific Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Boston Scientific Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, BSX's PE ratio (Price to Earnings) is 87.28 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.167 (multiply by 100 for percentage) rate of return.

Market Summary

BSX Alerts

BSX Stock Price

BSX RSI Chart

BSX Alerts

BSX Valuation

BSX Price/Sales (Trailing)

BSX Profitability

BSX Fundamentals

BSX Revenue

BSX Earnings

Price Action

How does BSX drawdown profile look like?

BSX Financial Health

BSX Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for BSX

Which funds bought or sold BSX recently?

Latest Funds Activity

Schedule 13G FIlings of Boston Scientific Corp

Recent SEC filings of Boston Scientific Corp

BSX Fair Value

Peers (Alternatives to Boston Scientific Corp)

Boston Scientific Corp News

Financials for Boston Scientific Corp

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

BSX Income Statement

BSX Balance Sheet

About Boston Scientific Corp

Boston Scientific Corp Frequently Asked Questions

What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

What is the market capital of Boston Scientific Corp (BSX)?

What is the fair value of BSX stock?

Is Boston Scientific Corp a good stock to buy?

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on Boston Scientific Corp's stock?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)